Item 8.01 Other Events
As previously reported, on April 14, 2020, Adamis Pharmaceuticals Corporation
(the "Company") received a letter from the Listing Qualifications Department of
The NASDAQ Capital Market ("Nasdaq") notifying the Company that it has been
granted an additional 180-day compliance period or until October 5, 2020, to
regain compliance with the minimum $1.00 bid price per share requirement of
Nasdaq's Marketplace Rule 5550(a)(2) (the "Rule"). On April 21, 2020, the
Company received an additional notice from Nasdaq (the "Tolling Notice"), which
stated that, due to current market conditions, Nasdaq has determined to toll the
compliance period for the Rule through June 30, 2020. As a result, the new date
by which the Company has to regain compliance with the Rule is December 21,
2020.
The Tolling Notice does not impact the Company's listing on The Nasdaq Capital
Market at this time. To regain compliance, the closing bid price of the
Company's common stock must be at least $1.00 per share for a minimum of 10
consecutive business days at any time prior to December 21, 2020.
© Edgar Online, source Glimpses